BackCellectar Biosciences Overview
Cellectar Biosciences Inc

Cellectar Biosciences Return on Equity

Valuation check: CLRB's ROE is -115.34%, below the Healthcare sector average of 13.1%.

Get informed when a big investor buys or sells

+ Follow

ROE

-115.34%

Return on Equity

-115.34%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Cellectar Biosciences (CLRB) FAQ

Cellectar Biosciences (CLRB) currently reports a ROE of -115.34%. That is below the Healthcare sector average of 13.1%. Use the charts on this page to explore Cellectar Biosciences's ROE history and peer comparisons.

Cellectar Biosciences's ROE of -115.34% is lower than the Healthcare sector average of 13.1%. That is roughly 980.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Cellectar Biosciences's current -115.34% should be judged against Healthcare norms (sector average: 13.1%) and against CLRB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -115.34%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for Cellectar Biosciences, and consider following CLRB for alerts when major investors trade the stock.

Cellectar Biosciences is classified in the Healthcare sector. On ROE, it currently shows -115.34% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CLRB with unrelated industries.